The SUMMIT Study

  • Home
  • The SUMMIT Study

Important COVID-19 notice

University College London Hospital is pleased to be restarting its SUMMIT Study nodule follow-up appointments from 6 July 2020.

Find out more information on the restart of the SUMMIT Study.

If you have any questions in regards to this, please email


UCLH is carrying out the SUMMIT study to detect lung cancer early using low-dose CT (LDCT) screening of at-risk individuals and to support development of a new blood test for early detection of multiple cancer types. Interested practices will need to sign up for the study, register your interest here.

The SUMMIT Study, beginning in spring 2019, has two aims: to detect lung cancer early using the proven method of low-dose CT (LDCT) screening of at-risk individuals; and to support development of a new blood test for early detection of multiple cancer types, including lung cancer. In addition, the study will provide evidence to inform a potential future national lung cancer screening programme. The study aims to recruit approximately 50,000 people aged 50-77 from north and east London.

How can my practice get involved?

UCLH and UCL are working closely with NOCLOR to engage GP practices in The SUMMIT Study. NOCLOR recently contacted practices in Camden with further information about the study and how to get involved.

Practices can register their interest to participate directly with NOCLOR. Find out further information about taking part as a practice. A payment of £250 will be provided for participation. The study would not disrupt your normal surgery routine.

If you have any questions, contact the study team on

Find out more information on the SUMMIT study

About The SUMMIT Study


SUMMIT lung cancer screening – Information Governance

Download DOCX, 12.51 KB